Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2015', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Hepatocellular Carcinoma (HCC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Hepatocellular Carcinoma (HCC) Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 9
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 10
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 11
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 15
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 16
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 17
Active Biotech AB 17
AstraZeneca PLC 18
Celgene Corporation 19
F. Hoffmann-La Roche Ltd. 20
Hutchison MediPharma Limited 21
Kyowa Hakko Kirin Co., Ltd. 22
MedImmune, LLC 23
Mirna Therapeutics, Inc. 24
Novartis AG 25
OncoMed Pharmaceuticals, Inc. 26
Onyx Pharmaceuticals, Inc. 27
Pfizer Inc. 28
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AZD-9150 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CC-122 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cell Therapy for Metastatic Hepatocellular Carcinoma - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
codrituzumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dusigitumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
erismodegib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HMPL-012 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ipafricept - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MRX-34 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
oprozomib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OSU-2S - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PF-04518600 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
tasquinimod - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
tivozanib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
UPO-901 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates 63
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 82
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 83
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 84
Featured News & Press Releases 84
Oct 09, 2013: Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study 84
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 84
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2015 9
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Active Biotech AB, H1 2015 17
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca PLC, H1 2015 18
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H1 2015 19
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 20
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Hutchison MediPharma Limited, H1 2015 21
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 22
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MedImmune, LLC, H1 2015 23
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H1 2015 24
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H1 2015 25
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 26
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 27
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H1 2015 63
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H1 2015 82
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H1 2015 83